针对NEDD4L-eEF1A1轴在癌症治疗中的治疗潜力
Yan Qin1,2,3,4, Xinyue Wang2, Minghui Zhao4,5
1Central Laboratory, Affiliated Hospital of Hebei University, Baoding 071000, China.
Acta biochimica et biophysica Sinica
|June 26, 2025
概括
神经元前体细胞表达发育下调4样 (NEDD4L) 通过降解内皮细胞中的eEF1A1来抑制瘤血管生成. 损失NEDD4L促进瘤生长和血管生成,突出显示NEDD4L-eEF1A1轴作为治疗点.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- 内皮细胞的增殖和迁移对于瘤血管生成至关重要.
- 神经元前体细胞表达发育下调的4-样 (NEDD4L),E3泛素酶,与瘤发生有关.
- 在内皮细胞和瘤血管生成中NEDD4L的特定功能需要阐明.
研究的目的:
- 研究NEDD4L在人类静脉内皮细胞 (HUVEC) 功能中的作用.
- 确定NEDD4L对瘤血管生成的影响.
- 阐明NEDD4L在内皮细胞中的功能背后的分子机制.
主要方法:
- 在HUVEC中过度表达NEDD4L.
- 细胞增殖和迁移试验的评估.
- 自活动的分析. 自活动的分析.
- 蛋白质基因分析和无处可见性测试用于识别相互作用的蛋白质和无处可见性模式.
- 使用小鼠模型进行体内研究,以评估瘤生长和血管生成.
主要成果:
- NEDD4L过度表达抑制了HUVEC的扩散和迁移.
- 在过度表达NEDD4L的细胞中,自活动增加.
- 发现NEDD4L与eEF1A1.1的K48相关的随处化介导降解相互作用并促进其降解.
- 失去内皮NEDD4L显著增强了瘤生长和血管生成 in vivo.
结论:
- 通过调节eEF1A1的无化和降解,NEDD4L可以抑制瘤血管生成.
- NEDD4L-eEF1A1轴是内皮细胞功能和瘤血管生成的关键调节器.
- NEDD4L代表了抑制瘤血管生成的潜在治疗标.
相关概念视频
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


